Boryung

003850 · KOSPI · Health Care · SMALL CAP

Net income turned to a loss.

Boryung filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$237M (+12.3% year on year), operating profit of US$19.2M (−13.4% year on year) and a net loss of US$9.95M (from a profit a year earlier).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-10-22· RCEPT 20261022800186

US$237MRevenue
+12.3%Revenue vs a year earlier
US$19.2MOperating profit

Converted at 1 USD ≈ ₩1,324.93 (filing-date rate, 2026-10-21 close)

What happened

Boryung filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$237M (+12.3% year on year), operating profit of US$19.2M (−13.4% year on year) and a net loss of US$9.95M (from a profit a year earlier).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$237M
Revenue vs a year earlier+12.3%
Operating profitUS$19.2M
Net income−US$9.95M
PeriodQ3 2026 (consolidated)
Filed2026-10-22, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20261022800186 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-10-22 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.